2016 ACR/ARHP Annual Meeting

November 11-16, 2016. Washington, DC.

View by Number View by Title View Sessions

View by Date

Sunday, November 13, 2016

9:00AM-11:00AM: Abstract Number: 501

Use of Rheumatologic Testing By Primary Care Physicians in Patients with Inflammatory Arthritis

Rheumatoid Arthritis – Clinical Aspects - Poster I: Clinical Characteristics/Presentation/Prognosis

9:00AM-11:00AM: Abstract Number: 417

Use of Tumor Necrosis Factor-α Inhibitors in Pediatric HLA-B27-Associated Uveitis

Pediatric Rheumatology – Clinical and Therapeutic Aspects - Poster I: Juvenile Idiopathic Arthritis, Uveitis

9:00AM-11:00AM: Abstract Number: 390

Use, Safety and Efficacy of Zrc 3197, a Biosimilar Candidate for Reference Adalimumab (Humira) from a Tertiary Pediatric Rheumatology Centre in India

Pediatric Rheumatology – Clinical and Therapeutic Aspects - Poster I: Juvenile Idiopathic Arthritis, Uveitis

9:00AM-11:00AM: Abstract Number: 502

Use, Usability and Feasibility of a Mapp for Patients with Rheumatoid Arthritis – First Results

Rheumatoid Arthritis – Clinical Aspects - Poster I: Clinical Characteristics/Presentation/Prognosis

9:00AM-11:00AM: Abstract Number: 305

Using a Large Prospective Cohort of Patients to Examine Differences in Performance and Self-Reported Outcomes Following Total Knee Replacement

Osteoarthritis – Clinical Aspects - Poster I

9:00AM-11:00AM: Abstract Number: 787

Using the American College of Rheumatology and Systemic Lupus International Collaborating Clinics Criteria to Measure Disease Severity in Discoid Lupus Erythematosus

Systemic Lupus Erythematosus – Clinical Aspects and Treatment - Poster I: Clinical Trial Design and Current Therapies

9:00AM-11:00AM: Abstract Number: 862

Utility of 18f FDG Positron Emission Tomography (PET) As a Diagnostic Test and Marker of Disease Activity in Large Vessel Vasculitis

Vasculitis - Poster I: Large Vessel Vasculitis and Polymyalgia Rheumatica

9:00AM-11:00AM: Abstract Number: 545

Utility of Power Doppler Ultrasound-Detected Synovitis for the Prediction of Short Term Flare in Rheumatoid Arthritis Patients in Clinical Remission

Rheumatoid Arthritis – Clinical Aspects - Poster I: Clinical Characteristics/Presentation/Prognosis

9:00AM-11:00AM: Abstract Number: 908

Utilization of Multiple Acute Phase Proteins and Biomarkers for Giant Cell Arteritis – Insight into Diagnosis and Clinical Complications

Vasculitis - Poster I: Large Vessel Vasculitis and Polymyalgia Rheumatica

9:00AM-11:00AM: Abstract Number: 416

Uveitis Associated to Polyarticular Juvenile Idiopathic Arthritis

Pediatric Rheumatology – Clinical and Therapeutic Aspects - Poster I: Juvenile Idiopathic Arthritis, Uveitis

9:00AM-11:00AM: Abstract Number: 553

Validation of Index of Activity Speed (Timed Up and Go test) for Outcome Measure of Patients with Long-Standing Rheumatoid Arthritis: Multicenter Prospective Cohort Study for Evaluation of Joint Surgery on Physical Function

Rheumatoid Arthritis – Clinical Aspects - Poster I: Clinical Characteristics/Presentation/Prognosis

9:00AM-11:00AM: Abstract Number: 455

Validity, Reliability and Sensitivity to Change of Four Different Patient-Reported Outcomes (PROs) to Measure the Domains Pain, Fatigue, Experienced Disease Activity and General Well-Being in Patients with Rheumatoid Arthritis

Quality Measures and Quality of Care - ARHP Poster

9:00AM-11:00AM: Abstract Number: 886

Vascular Inflammation Assessed By 18f-Fludeoxyglucose Positron Emission Tomography (FDG-PET) Is Modified By Treatment in Patients with Large Vessel Vasculitis

Vasculitis - Poster I: Large Vessel Vasculitis and Polymyalgia Rheumatica

9:00AM-11:00AM: Abstract Number: 66

Very Rare X Chromosome Abnormalities in SLE and SjöGren’s May Localize X Gene Dose Effect

Genetics, Genomics and Proteomics - Poster I

9:00AM-11:00AM: Abstract Number: 290

Viscosupplemenation Efficacy in Knee Oa Is Similar in Single-Injection Vs. Multi-Week Formulations and Across OA Severity and BMI Subgroups, but Better in Younger Patients

Osteoarthritis – Clinical Aspects - Poster I

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].